Beneficial ownership — 13D / 13G
87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| AWM Investment Company, Inc. | BRCNF Burcon NutraScience Corp | 13G | 6.7% | Dec 31, 2023 | 2y |
| Thomas A. Satterfield, Jr. | ALCO Alico, Inc. | 13G/A | 7.52% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | XRTX XORTX Therapeutics Inc. | 13G/A | 4.99% | Dec 31, 2023 | 2y |
| FRONTIER CAPITAL MANAGEMENT CO.,LLC | TILE Interface Inc | 13G/A | 5.23% | Dec 31, 2023 | 2y |
| Ronald M. Shaich | CAVA Cava Group, Inc. | 13G | 10.3% | Dec 31, 2023 | 2y |
| Nan Shan Life Insurance Co., Ltd. | TRTX TPG RE Finance Trust, Inc. | 13G/A | 3.67% | Dec 31, 2023 | 2y |
| Deer IX & Co. L.P. | TOST Toast, Inc. | 13G/A | 4% | Dec 31, 2023 | 2y |
| Park West Asset Management LLC | UTI Universal Technical Institute Inc | 13G/A | 5.3% | Dec 31, 2023 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | HIG Hartford Insurance Group, Inc. | 13G/A | 6.2% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | BFRI Biofrontera Inc. | 13G | 9.99% | Dec 31, 2023 | 2y |
| Deep Track Capital, LP | ESPR Esperion Therapeutics, Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| FIR TREE CAPITAL MANAGEMENT LP | PFTA Perception Capital Corp. III Class A Ordinary Share | 13G | 5.08% | Dec 31, 2023 | 2y |
| Deep Track Capital, LP | IMVT Immunovant, Inc. | 13G/A | 0.69% | Dec 31, 2023 | 2y |
| Newtyn Management, LLC | TECX Tectonic Therapeutic, Inc. | 13G | 6.1% | Dec 31, 2023 | 2y |
| Driehaus Capital Management LLC | XENE Xenon Pharmaceuticals Inc. | 13G/A | 5.88% | Dec 31, 2023 | 2y |
| Lytton, Laurence W. | BIOL Biolase, Inc. | 13G/A | 0.6% | Dec 31, 2023 | 2y |
| Aristotle Capital Management, LLC | RPM Rpm International Inc | 13G/A | 7.43% | Dec 31, 2023 | 2y |
| Fund 1 Investments, LLC | JILL J.Jill, Inc. | 13G/A | 3.36% | Dec 31, 2023 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | ENTG Entegris Inc | 13G | 8.1% | Dec 31, 2023 | 2y |
| MARSHFIELD ASSOCIATES | STRA Strategic Education, Inc. | 13G/A | 7.61% | Dec 31, 2023 | 2y |
| BIOTECHNOLOGY VALUE FUND L P | ELDN Eledon Pharmaceuticals, Inc. | 13G/A | 17.9% | Dec 31, 2023 | 2y |
| EcoR1 Capital, LLC | KURA Kura Oncology, Inc. | 13G/A | 9.99% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | SCNI Scinai Immunotherapeutics Ltd. | 13G | 9.99% | Dec 31, 2023 | 2y |
| Third Rock Ventures IV, L.P. | FULC Fulcrum Therapeutics, Inc. | 13G/A | 3.8% | Dec 31, 2023 | 2y |
| Cormorant Asset Management, LP | ATXS Astria Therapeutics, Inc. Common Stock | 13G/A | 0% | Dec 31, 2023 | 2y |
| 683 Capital Management, LLC | CDLX Cardlytics, Inc. | 13G/A | 4.6% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | FSBC Five Star Bancorp | 13G | 8% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | PALI Palisade Bio, Inc. | 13G/A | 4.99% | Dec 31, 2023 | 2y |
| ALLIANCEBERNSTEIN L.P. | ATRC AtriCure, Inc. | 13G/A | 7.2% | Dec 31, 2023 | 2y |
| BIOTECHNOLOGY VALUE FUND L P | CNTA Centessa Pharmaceuticals plc | 13G/A | 9% | Dec 31, 2023 | 2y |
| Shay Capital LLC | XELA Exela Technologies, Inc. Common Stock | 13G/A | 8.23% | Dec 31, 2023 | 2y |
| Westchester Capital Management, LLC | ALSAF Alpha Star Acquisition Corp | 13G | 7.17% | Dec 31, 2023 | 2y |
| FRONTIER CAPITAL MANAGEMENT CO.,LLC | MOD Modexus Solutions, Inc. | 13G/A | 2.86% | Dec 31, 2023 | 2y |
| Tarsadia Capital, LLC | SHO Sunstone Hotel Investors, Inc. | 13G/A | 2.2% | Dec 31, 2023 | 2y |
| Fundsmith LLP | MKC Mccormick & Co Inc | 13G/A | 7.6% | Dec 31, 2023 | 2y |
| NOMURA HOLDINGS INC | AYRWF Ayr Wellness Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Hugh S. Griffith | NCNA NuCana plc | 13G/A | 11% | Dec 31, 2023 | 2y |
| RTW INVESTMENTS, LP | SABS SAB Biotherapeutics, Inc. | 13G | 9.99% | Dec 31, 2023 | 2y |
| CONTINENTAL GENERAL INSURANCE CO | SDIG Stronghold Digital Mining, Inc. Class A Common Stock | 13G/A | 9.99% | Dec 31, 2023 | 2y |
| Hillhouse Investment Management, Ltd. | LEGN Legend Biotech Corp | 13G/A | 3.6% | Dec 31, 2023 | 2y |
| RTW INVESTMENTS, LP | IMUX Immunic, Inc. | 13G/A | 9.6% | Dec 31, 2023 | 2y |
| GLAZER CAPITAL, LLC | MVLA Movella Holdings Inc. Common Stock | 13G/A | 0% | Dec 31, 2023 | 2y |
| Nuveen Asset Management, LLC | ALT Altimmune, Inc. | 13G/A | 2.88% | Dec 31, 2023 | 2y |
| ALLIANCEBERNSTEIN L.P. | RMBI Richmond Mutual Bancorporation, Inc. | 13G/A | 7.2% | Dec 31, 2023 | 2y |
| BAKER BROS. ADVISORS LP | ADAPY Adaptimmune Therapeutics PLC | 13G/A | 4.8% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | ALHC Alignment Healthcare, Inc. | 13G | 6.4% | Dec 31, 2023 | 2y |
| Olivier Pomel | DDOG Datadog, Inc. | 13G/A | 6.1% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | QTEX QTREX Quantum Ltd. | 13G | 9.89% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | ACHC Acadia Healthcare Company, Inc. | 13G/A | 9.3% | Dec 31, 2023 | 2y |
| Greenhouse Funds LLLP | CDRE Cadre Holdings, Inc. | 13G | 6.6% | Dec 31, 2023 | 2y |